Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics (MGX) has recorded zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating operational stability in our near-term monitoring window. However, low signal in a 90-day window does not mean low risk; the biotech sector carries inherent dilution and financing pressures that require deeper context. The full $49 Report extends analysis to 12 months of filing history, quantifies shareholder dilution risk, maps the company's financing trajectory, and flags AI-detected risk signals in capital structure and governance. The full $49 Report adds dilution risk scoring, 12-month red-flag context, financing runway analysis, and AI risk signals.